Decreased soluble dipeptidyl peptidase IV activity as a potential serum biomarker for COPD

Clinical Biochemistry

Volumn 45, Issue 15, 2012, Pages 1245-1250

  Somborac Bačura, Anita ^a   Buljević, Sunčica ^b   Rumora, Lada ^a   Čulić, Ognjen ^c   Detel, Dijana ^b   Pancirov, Dolores ^d   Popović Grle, Sanja ^e   Varljen, Jadranka ^b   Čepelak, Ivana ^a   Žanić Grubišić, Tihana ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

^c Department of Biochemistry and Hematology Diagnosis ^*  (Croatia)

^d Dr Ivo Pedi i General Hospital   (Croatia)

^e KBC Zagreb   (Croatia)

Author keywords

Biomarker; C reactive protein; Chronic obstructive pulmonary disease; GOLD stage; Soluble dipeptidyl peptidase IV activity

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV; SOLUBLE DIPEPTIDYL PEPTIDASE 4; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 84866306618     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.04.023     Document Type: Article

References (43)

1. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive, pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22:672-688.
2. Celli B.R., MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
3. Cazzola M., MacNee W., Martinez F.J., Rabe K.F., Franciosi L.G., Barnes P.J., et al. American Thoracic Society, European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469.
4. Noguera A., Batle S., Miralles C., Iglesias J., Busquets X., MacNee W., et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001, 56:432-437.
5. Fairclough L., Urbanowicz R.A., Corne J., Lamb J.R. Killer cells in chronic obstructive pulmonary disease. Clin Sci (Lond) 2008, 114:533-541.
6. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519.
7. Wüst R.C., Degens H. Factors contributing to muscle wasting and dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis 2007, 2:289-300.
8. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
9. Dickens J.A., Miller B.E., Edwards L.D., Silverman E.K., Lomas D.A., Tal-Singer R. Eclipse Study Investigators EO. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011, 12:146.
10. Patel A.R., Hurst J.R., Wedzicha J.A. The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. Semin Respir Crit Care Med 2010, 31:267-275.
11. Larsson K. Infammatory markers in COPD. Clin Respir J 2008, 2(Suppl. 1):84-87.
12. Torres-Ramos Y.D., García-Guillen M.L., Olivares-Corichi I.M., Hicks J.J. Correlation of plasma protein carbonyls and c-reactive protein with GOLD stage progression in COPD patients. Open Respir Med J 2009, 14:61-66.
13. Kolsum U., Roy K., Starkey C., Borrill Z., Truman N., Vestbo J., et al. The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis 2009, 4:149-156.
14. Gan W.Q., Man S.F., Sin D.D. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005, 127:558-564.
15. Piehl-Aulin K., Jones I., Lindvall B., Magnuson A., Abdel-Halim S.M. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. Respiration 2009, 78:191-196.
16. Lambeir A.M., Durinx C., Scharpé S., De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003, 40:209-294.
17. Cordero O.J., Salgado F.J., Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 2009, 58:1723-1747.
18. Landis B.N., Grouzmann E., Monod M., Busso N., Petak F., Spiliopoulos A., et al. Implication of dipeptidylpeptidase IV activity in human bronchial inflammation and in bronchoconstriction evaluated in anesthetized rabbits. Respiration 2008, 75:89-97.
19. Grouzmann E., Monod M., Landis B., Wilk S., Brakch N., Nicoucar K., et al. Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J 2002, 16:1132-1134.
20. Matsuno O., Miyazaki E., Nureki S., Ueno T., Ando M., Kumamoto T. Soluble CD26 is inversely associated with disease severity in patients with chronic eosinophilic pneumonia. Biomark Insights 2007, 1:201-204.
21. Cuchacovich M., Gatica H., Pizzo S.V., Gonzalez-Gronow M. Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmunediseases. Clin Exp Rheumatol 2001, 19:673-680.
22. Varljen J., Mijandrušić Sinčić B., Batičić L., Varljen N., Detel D., Lekić A. Clinical relevance of the serum dipeptidyl peptidase IV (DPP IV/CD26) activity in adult patients with Crohn's disease and ulcerative colitis. Croat Chem Acta 2005, 78:427-432.
23. Detel D., Peršić M., Varljen J. Serum and intestinal dipeptidyl peptidase IV (DPP IV/CD26) activity in children with celiac disease. J Pediatr Gastroenterol Nutr 2007, 45:65-70.
24. Nagatsu T., Hino M., Fuyamada H., Hayakawa T., Sakakibara S. New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase. Anal Biochem 1976, 74:466-476.
25. Matheeussen V., Lambeir A.M., Jungraithmayr W., Gomez N., Mc Entee K., Van der Veken P., et al. Method comparison of dipeptidyl peptidase activity assays and their application in biological samples containing reversible inhibitors. Clin Chim Acta 2012, 413:456-462.
26. Durinx C., Neels H., Van der Auwera J.C., Naelaerts K., Scharpe S., De Meester I. Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 2001, 39:155-159.
27. Dati F., Schumann G., Thomas L., Aguzzi F., Baudner S., Bienvenu J., et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP Reference Material (CRM 470). International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem 1996, 34(6):517-520.
28. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39:561-577.
29. Van Der Velden V.H., Naber B.A., Van Hal P.T., Overbeek S.E., Hoogsteden H.C., Versnel M.A. Peptidase activities in serum and bronchoalveolar lavage fluid from allergic asthmatics - comparison with healthy non-smokers and smokers and effects of inhaled glucocorticoids. Clin Exp Allergy 1999, 29:813-823.
30. Remes S.T., Delezuch W., Pulkki K., Pekkanen J., Korppi M., Matinlauri I.H. Association of serum-soluble CD26 and CD30 levels with asthma, lung function and bronchial hyper-responsiveness at school age. Acta Paediatr 2011, 100:e106-e111.
31. + T lymphocytes costimulatory molecule CD26 in adult patients with allergic asthma. J Clin Immunol 2007, 27:430-437.
32. Ohnuma K., Yamochi T., Hosono O., Morimoto C. CD26 T cells in the pathogenesis of asthma. Clin Exp Immunol 2005, 139:13-16.
33. Boonacker E.P., Wierenga E.A., Smits H.H., Van Noorden C.J. CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry. J Histochem Cytochem 2002, 50:1169-1177.
34. Busso N., Wagtmann N., Herling C., Chobaz-Péclat V., Bischof-Delaloye A., So A., et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005, 166:433-442.
35. van der Velden V.H., Wierenga-Wolf A.F., Adriaansen-Soeting P.W., Overbeek S.E., Möller G.M., Hoogsteden H.C., et al. Expression of aminopeptidase N and dipeptidyl peptidase IV in the healthy and asthmatic bronchus. Clin Exp Allergy 1998, 28:110-120.
36. De Chiara L., Rodríguez-Piñeiro A.M., Cordero O.J., Rodríguez-Berrocal F.J., Ayude D., Rivas-Hervada And F.J., et al. Soluble CD26 levels and its association to epidemiologic parameters in a sample population. Dis Markers 2009, 27:311-316.
37. Maes M., Scharpé S., De Meester I., Goossens P., Wauters A., Neels H., et al. Components of biological variations in prolyl endopeptidase and dipeptidyl-peptidase IV activity in plasma of healthy subjects. Clin Chem 1994, 40:1686-1691.
38. Hacker S., Lambers C., Hoetzenecker K., Pollreisz A., Aigner C., Lichtenauer M., et al. Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction. Clin Lab 2009, 55:31-40.
39. Man S.F.P., Connett J.E., Anthonisen N.R., Wise R.A., Tashkin D.P., Sin D.D. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61:849-853.
40. de Torres J.P., Pinto-Plata V., Casanova C., Mullerova H., Córdoba-Lanús E., Muros de Fuentes M., et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008, 133:1336-1343.
41. Rumora L., Milevoj L., Popović-Grle S., Barišić K., Čepelak I., Žanić Grubišić T. Levels changes of blood leukocytes and intracellular signalling pathways in COPD patients with respect to smoking attitude. Clin Biochem 2008, 41:387-394.
42. Garcia-Rio F., Miravitlles M., Soriano J.B., Muñoz L., Duran-Tauleria E., Sánchez G., et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010, 11:63-77.
43. Rumora L., Milevoj L., Popović-Grle S., Barišić K., Žanić Grubišić T., Čepelak I. Reduction in peripheral blood leukocyte heat shock proteins 27 and 70 expression in chronic obstructive pulmonary disease. Clin Chim Acta 2008, 81:73-80.